Hospira HSP

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
    1. New Morningstar Analyst Report for Fresenius SE & Co KGaA

      Stock Reports

      Thu, 11 Sep 2014

      need to maintain a close eye on manufacturing and quality control processes to avoid suffering a similar fate to peers such as Hospira . Remediation costs for Fresenius' regulatory issues appear relatively immaterial for the time being. Although a minor concern

    2. New Morningstar Analyst Report for Amgen Inc

      Stock Reports

      Thu, 11 Sep 2014

      dialysis drug payments), potential branded competition (Mircera as early as 2014), and biosimilar launches (including Hospira in 2016). For neutropenia drugs Neupogen and Neulasta, we see sales declining from $5.8 billion in 2013 to $4.3 billion

    3. Hospira may cut sales staff after losing Precedex case

      Headlines

      Mon, 8 Sep 2014

      rules that sales of generic versions of Hospira 's ( HSP -2.1% ) proprietary sedative ..... introduction of generic formulations. Hospira has filed an appeal of the decision and ..... version. Despite the adverse ruling, Hospira reaffirms its 2014 EPS guidance of $2

    4. Exclusive: Hospira talks with Danone on $5 billion tax inversion deal stall

      Headlines

      Wed, 3 Sep 2014

      LONDON (Reuters) - U.S. drugmaker Hospira ’s HSP.N talks to buy the medical nutrition unit of Danone DANO.PA and use the deal to move its tax domicile abroad have

    5. Not so fast, Mylan

      Headlines

      Wed, 20 Aug 2014

      allow the sale of generic versions of Hospira 's ( HSP +1.4% ) sedative Precedex ..... injection) In its lawsuit filed yesterday, Hospira claims that the agency violated its own ..... intensive care unit sedation) covered by Hospira 's patent. In his order, Judge Jarrod

    6. U.S. judge blocks FDA rule allowing generic versions of Hospira drug

      Headlines

      Wed, 20 Aug 2014

      Aug 20 (Reuters) - A federal judge has issued a temporary restraining order against the U.S. Food and Drug Administration's decision to allow the sale of generic versions of the Hospira Inc sedative Precedex.

    7. Mylan launches generic version of Precedex

      Headlines

      Tue, 19 Aug 2014

      Mylan ( MYL +1.3% ) launches dexmedetomidine hydrochoride injection, 100 mcg (base)/mL, the therapeutic equivalent of Hospira 's ( HSP -2.8% ) Precedex . The U.S. market is ~$156M. Mylan has 295 ANDAs pending FDA approval representing

    8. UPDATE 1-Top U.S. lawmaker urges Hospira not to flee tax system

      Headlines

      Thu, 14 Aug 2014

      (Adds details of Durbin letter, Wyden comment, background, byline)

    9. Senior U.S. lawmaker urges Hospira not to flee U.S. tax system

      Headlines

      Thu, 14 Aug 2014

      WASHINGTON, Aug 14 (Reuters) - A senior U.S. senator said on Thursday he has written to the chief executive of Hospira Inc and urged the drug and medical device maker not to move its tax domicile...

    10. New Morningstar Analyst Report for Cubist Pharmaceuticals Inc

      Stock Reports

      Wed, 13 Aug 2014

      Cubicin is facing a patent challenge from Hospira .If Cubist's CB-315/Surotomycin ..... news was a big win for Cubist, but Hospira has now also challenged the drug's patent. There is a risk that Hospira could prevail in litigation, and Cubicin

    « Prev12345Next »
    Content Partners